Abivax SA (FR:ABVX)
:ABVX
Want to see FR:ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
€104.70
-€0.19(-2.81%)
At close: 4:00 PM EST
€104.70
-€0.19(-2.81%)
Day’s Range― - ―
52-Week Range€5.00 - €132.00
Previous CloseN/A
Volume4.35K
Average Volume (3M)99.97K
Market Cap
€7.62B
Enterprise Value€7.67B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€32.09M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 25, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding79,694,534
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€125.00Price Target Upside19.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.45
Revenue Forecast (FY)€3.14M
Bulls Say, Bears Say
Bulls Say
Improved 2025 Balance SheetA materially stronger 2025 balance sheet with low leverage (~7% debt-to-equity) and higher equity provides durable financing flexibility for clinical development. This reduces near-term insolvency risk, lengthens runway, and makes future R&D investment or strategic partnerships easier without immediate revenue dependence.
High Historical Gross MarginsWhen revenue was present the company reported near-100% gross margins, indicating a scalable cost structure typical of small-molecule/biotech products. If clinical programs succeed and commercialization occurs, margins could be structurally high, supporting long-term profitability potential once fixed R&D and SG&A are covered.
Focused Clinical-Stage PipelineA clear, focused pipeline centered on an oral small-molecule (obefazimod) concentrates R&D resources and clinical expertise, increasing the chance of clinical progress. For a clinical-stage biotech, a single promising, differentiable candidate provides durable upside through milestones, licensing or partnership opportunities.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (around -162M in 2025) means the company cannot self-fund its development program. Over months this necessitates continued external financing, increasing dilution risk, potential covenant pressure, and dependence on capital markets or partners to sustain long-term R&D.
No Commercial Revenue In 2025A complete absence of commercial revenue in 2025 underscores the company's lack of product commercialization and revenue diversification. Without product sales, operating losses persist and the business remains entirely funded by financing or deals, limiting its ability to demonstrate sustainable cash generation over the next 2–6 months.
Widening Losses And Funding RelianceDeepening operating and net losses combined with historical swings in leverage show the company has relied on capital raises and restructuring to operate. Structurally, this pattern raises execution and financing risk: future development depends on successful funding or partnerships, which can dilute shareholders and constrain strategic choices.
Abivax SA News
ABVX FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €5.00 and its highest was €132.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.62B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is May 25, 2026 which is in 4 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Mar 23, 2026. The company reported -€1.04 earnings per share for the quarter, beating the consensus estimate of -€1.161 by €0.121.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.8.
How many shares outstanding does Abivax SA have?
Abivax SA has 79,694,534 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.04 in its last earnings report, beating expectations of -€1.161. Following the earnings report the stock price went down -3.755%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in FR:ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
€125.00
▲(19.39% Upside)
Technical Analysis
Options Prices
Currently, No data available
---